The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global renal denervation systems market size reached US$ 218.2 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,723.6 Million by 2027, exhibiting a growth rate (CAGR) of 40.67% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Renal denervation (RDN) is an interventional procedure that involves a catheter-based ablation of the sympathetic nerves within the renal artery wall. It maximizes nerve disruption, lowers renin secretion, stimulates natriuresis, and improves renal hemodynamics or blood flow. As a result, RDN systems are extensively used to treat refractory hypertension cases wherein optimal therapy cannot provide relief to the patients.
A significant rise in the prevalence of lifestyle diseases, such as hypertension, on account of the increasing number of individuals who smoke and consume alcohol, rising unhealthy dietary patterns, sedentary and hectic lifestyles, and the growing geriatric population represents, one of the key factors strengthening market growth. Apart from this, the advantages associated with the RDN system, such as fast recovery, safety, time efficiency and cost-effectiveness, are acting as another major growth-inducing factor. Furthermore, the escalating demand for minimally invasive (MI) surgery is also contributing to the growth of the market. The introduction of micro-infusion technology, improving healthcare infrastructure, increasing research and development (R&D) activities and the rising number of filings for regulatory approvals of the systems, are also creating a positive influence on the market growth. Although, a decline in the hospital visits and rescheduling of elective health procedures due to the surging cases of the coronavirus disease (COVID-19) have impacted the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global renal denervation systems market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, product, technology, application and end user.
Breakup by Product Type:
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Boston Scientific Group, Kona Medical Inc., Medtronic Plc, Mercator MedSystems, ReCor Medical Inc. (Otsuka Holdings Co. Ltd.), Renal Dynamics, St. Jude Medical Inc. (Abbott) and Terumo Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Product, Technology, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Boston Scientific Group, Kona Medical Inc., Medtronic Plc, Mercator MedSystems, ReCor Medical Inc. (Otsuka Holdings Co. Ltd.), Renal Dynamics, St. Jude Medical Inc. (Abbott) and Terumo Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at